Lale Tokgözoğlu: Significant CV Benefit of Lowering LDL to 44 mg/dL in Diabetes
Lale Tokgözoğlu, Professor of Cardiology at Hacettepe University, shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
“Our analysis from the Vesalius trial showed significant benefit of lowering LDL to a median of 44 mg/dL in diabetics presented at ACC26.”
Title: Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes Results From the VESALIUS-CV Trial
Authors: Nicholas A. Marston, Erin A. Bohula, Ajay K. Bhatia, Gaetano M. De Ferrari, Lawrence A. Leiter, Jose C. Nicolau, Jeong-Gun Park, Sabina A. Murphy, Emileigh Walsh, Lyrica Liu, Subodh Verma, Naveed Sattar, Stephen J. Nicholls, Jose Lopez-Sendon, Ioanna Gouni-Berthold, Lale Tokgozoglu, Ron Blankstein, Marcoli Cyrille, Gabriel Paiva da Silva Lima, Robert P. Giugliano, Marc S. Sabatine
Read the Full Article on Jama
More posts featuring Lale Tokgözoğlu on Hemostasis Today
-
Apr 3, 2026, 17:46Michelle Leona Cecil: A Call to Protect Patient Care and The Nation’s Blood Supply for Blood Disorders Community
-
Apr 3, 2026, 17:38Shahab Sheikhalishahi: A Rare Case of Portal Vein Thrombosis After Echis Carinatus Envenomation
-
Apr 3, 2026, 17:33Kimberly Ha: Epia Neuro Aims to Restore Movement in Stroke Survivors
-
Apr 3, 2026, 17:28Ryan Perry: Heart and Stroke Announces 2026 Grants-in-Aid Indigenous Research Stream Funding Opportunity
-
Apr 3, 2026, 17:21Maxime Dely: A Meaningful Journey of 14 years in Blood Transfusion
-
Apr 3, 2026, 17:19Arun V J: Don’t Miss TRANSCON 2026 – A Direct Pathway Into India’s Clinical and Institutional Network
-
Apr 3, 2026, 17:17Louise St. Germain Bannon: Preparating for ISTH 2026 and Highlighting Best Aspects of Congress
-
Apr 3, 2026, 17:15Jeremy Jacobs: The Political Misuse of ‘Patient Autonomy’ in Modern Law
-
Apr 3, 2026, 17:14Yves Bikorimana: When More Is Not Better – Polycythemia